seri
recombin
fusion
protein
deriv
equin
arter
viru
eav
open
read
frame
orf
use
defin
immunoreaet
region
viral
nucleocapsid
n
protein
reactiv
recombin
n
fusion
protein
postinfect
equin
sera
immunoblot
elisa
indic
major
nucleocapsid
protein
epitop
locat
within
amino
acid
residu
elisa
two
recombin
nucleocapsid
fusion
protein
contain
residu
discrimin
preand
postinfect
preand
postvaccin
serum
sampl
addit
detect
seroconvers
follow
vaccin
kill
viru
prepar
even
absenc
detect
viru
neutralis
respons
although
good
correl
exist
viru
neutralis
antibodi
elisa
posit
valu
postinfect
sera
rn
protein
fail
induc
viru
neutralis
respons
immunis
rabbit
equin
viral
arter
eva
debilit
diseas
hors
chirnsid
sever
caus
abort
doll
et
al
foal
death
golnik
et
al
vaala
et
al
diagnosi
complic
symptom
infect
extrem
vari
diseas
outbreak
may
remain
clinic
unappar
come
light
follow
serosurvey
equin
popul
viru
transmiss
vener
respiratori
rout
seroposit
stallion
perman
shed
equin
arter
viru
eav
semen
follow
infect
timoney
et
al
shed
stallion
use
breed
initi
spread
eva
mare
infect
shed
viru
bodi
fluid
viraem
phase
mccollum
et
al
may
infect
incontact
respiratori
rout
eav
singlestrand
positivesens
rna
viru
recent
classifi
genu
arteriviru
cavanagh
et
al
includ
lactat
dehydrogenaseelev
viru
kuo
et
al
godeni
et
al
simian
haemorrhag
fever
viru
plagemann
moennig
viru
caus
porcin
respiratori
reproduct
syndrom
prr
conzelmann
et
al
lelystad
viru
meulenberg
et
al
b
eav
virion
diamet
nm
hyllseth
consist
isometr
nucleocapsid
nm
surround
envelop
carri
ringlik
surfac
structur
diamet
nm
murphi
nucleocapsid
compos
infecti
polyadenyl
singlestrand
genom
rna
size
kb
den
boon
et
al
phosphoryl
core
protein
n
r
hyllseth
zeeger
et
al
envelop
contain
nonglycosyl
protein
nglycosyl
protein
r
g
g
l
de
vri
et
al
major
viral
structur
protein
gl
n
encod
open
read
frame
orf
respect
minor
envelop
glycoprotein
g
specifi
orf
de
vri
et
al
orf
predict
encod
nglycosyl
membran
protein
den
boon
et
al
howev
product
orf
characteris
viru
neutralis
monoclon
antibodi
direct
g
l
balasuriya
et
al
balasuriya
et
al
deregt
et
al
recombin
g
l
current
investig
subunit
vaccin
chirnsid
et
al
diagnost
test
antigen
chirnsid
et
al
g
l
prove
use
subunit
vaccin
antigen
serodiagnost
test
base
altern
viru
antigen
could
allow
differenti
discrimin
subunit
vaccin
seroposit
hors
would
aid
identif
natur
infect
seroposit
anim
particular
stallion
like
shed
eav
semen
could
consequ
reduc
risk
viru
transmiss
vener
rout
altern
protein
candid
use
diagnost
antigen
includ
eav
structur
protein
g
n
eav
g
compris
virion
protein
complex
glycosyl
structur
unlik
major
viral
antigen
de
vri
et
al
de
vri
analysi
protein
indic
hydrophob
like
submerg
within
viru
particl
de
vri
et
al
n
compris
total
virion
protein
notabl
hydrophob
fusion
protein
base
eav
g
n
react
elisa
viru
neutralis
equin
sera
chirnsid
et
al
rabbit
hamster
equin
antisera
recognis
eav
n
g
l
g
immunoprecipit
immunoblot
van
berlo
et
al
iwashita
harasawa
de
vri
et
al
paper
present
result
clone
fragment
eav
n
protein
bacteri
express
vector
pgex
produc
recombin
glutathionestransferas
fusion
protein
investig
reactiv
equin
sera
western
blot
elisa
restrict
enzym
deoxynucleosid
triphosph
solut
glutathion
sepharos
express
vector
obtain
pharmacia
calf
intestin
alkalin
phosphatas
lysozym
klenow
larg
fragment
dna
polymeras
dnase
dna
polymeras
dna
ligas
suppli
boehring
mannheim
sequenas
version
obtain
us
biochem
biotinlabel
affinitypurifi
goat
antiserum
hors
igg
streptavidin
peroxidas
conjug
kirkegaard
perri
laboratori
inc
plasmid
dna
manipul
perform
standard
method
sambrook
et
al
prokaryot
express
vector
direct
express
clone
dna
glutathionestransferas
gst
fusion
protein
chirnsid
et
al
control
iptg
induc
tac
promot
smith
johnson
eav
cdna
sequenc
encod
orf
origin
cdna
clone
de
vri
et
al
ligat
frame
tabl
transform
escherichia
coli
strain
gibson
recombin
select
luria
broth
lb
agar
contain
zg
ampicillin
per
ml
overnight
cultur
dilut
twentyfold
fresh
medium
grown
h
protein
express
induc
addit
iptg
mm
h
growth
ml
cultur
centrifug
bacteri
pellet
dissolv
sampl
buffer
incub
min
analys
sodium
dodecyl
sulphat
sd
polyacrylamid
gel
paa
stain
coomassi
brilliant
blue
visualis
separ
protein
doublestrand
dna
clone
express
alter
gst
fusion
protein
subject
restrict
endonucleas
analysi
recombin
plasmid
sequenc
sequenas
confirm
gsteav
dna
junction
correct
read
frame
sequenc
perform
use
primer
locat
approxim
bp
upstream
pgex
multipl
clone
site
addit
intern
eavspecif
primer
fusion
protein
affinitypurifi
use
glutathionesepharos
report
previous
chimsid
et
al
optim
concentr
reactant
determin
chequerboard
titrat
immulon
microtitr
plate
dynatech
coat
per
well
gst
gsteav
fusion
protein
elisa
perform
describ
previous
chirnsid
et
al
equin
sera
dilut
variabl
background
absorb
caus
nonspecif
bind
sera
gst
consequ
reactiv
serum
sampl
gst
subtract
gsteav
fusion
protein
deriv
eavspecif
absorb
valu
test
sera
assay
duplic
antigen
mean
absorb
nm
calcul
follow
electrophoret
transfer
protein
polyacrylamid
gel
onto
nitrocellulos
membran
immunoblot
perform
describ
previous
chirnsid
et
al
neutralis
titr
equin
sera
determin
describ
senn
et
al
minor
modif
chirnsid
et
al
new
zealand
white
rabbit
immunis
subcutan
zg
affinitypurifi
gst
gsteav
fusion
protein
freund
complet
adjuv
follow
week
later
second
immunis
freund
incomplet
adjuv
serum
collect
regular
interv
test
viru
neutralis
antibodi
eav
antisera
use
studi
submit
anim
health
trust
diagnost
laboratori
isol
vaccinespecif
equin
sera
kindli
provid
dr
fukunaga
japan
race
associ
characterist
nucleocapsid
gene
fusion
protein
relationship
given
tabl
complet
n
protein
fuse
carboxi
terminu
gst
express
remain
n
fusion
protein
contain
smaller
region
n
gene
although
recombin
protein
express
quantiti
follow
iptg
induct
fig
could
purifi
affin
gel
chromatograpi
glutathionesepharos
yield
follow
purif
reduc
compar
immunoblot
recombin
n
protein
eav
seroposit
seroneg
equin
sera
recognis
gst
fig
howev
strongli
bound
postinfect
equin
sera
fig
order
examin
reactiv
equin
sera
elisa
panel
consist
seroneg
equin
sera
use
control
eav
g
l
elisa
chirnsid
et
al
test
five
rn
protein
mean
absorb
sera
determin
seroneg
elisa
cutoff
point
calcul
antigen
mean
sd
recombin
protein
addit
postinfect
sera
vn
titr
rang
screen
determin
reactiv
rn
antigen
elisa
fail
react
specif
postinfect
sera
fig
react
sera
respect
whilst
react
postinfect
equin
sera
comparison
postinfect
sera
recognis
elisa
antisera
rabbit
immunis
recognis
gst
elisa
immunoblot
strongli
eavspecif
reactiv
mask
shown
antirn
sera
fail
neutralis
eav
vn
test
contrast
rabbit
equin
sera
exhibit
vn
antibodi
activ
chirnsid
et
al
result
elisa
compar
result
obtain
eav
vn
test
rg
l
elisa
chirnsid
et
al
use
panel
equin
sera
panel
compris
vnfield
sera
postinfect
sampl
intern
test
control
sera
hors
preand
two
week
postvaccin
artervac
fort
dodg
laboratori
vn
postvaccin
sampl
sera
rais
three
specif
eav
isol
bucyru
boldfac
repres
seroposit
result
vn
elisa
test
pre
prevaecin
serum
sampl
post
ffi
postvaccin
serum
sampl
nd
ffi
determin
vn
antibodi
titr
deem
seroposit
eav
vn
neutralis
test
b
cutoff
valu
determin
seroposit
statu
taken
mean
sd
vn
neg
control
sera
posit
c
cutoff
valu
determin
seroposit
statu
taken
mean
sd
vn
neg
control
sera
posit
cutoff
valu
determin
seroposit
statu
taken
mean
sd
vn
neg
control
sera
posit
ing
result
eav
vn
elisa
test
order
confirm
serum
antibodi
statu
result
elisa
vn
test
shown
tabl
seroposit
cutoff
valu
antigen
calcul
use
vnfield
sera
tabl
elisato
sera
elisa
test
serum
nm
margin
cutoff
valu
antigen
eight
postinfect
vn
sera
elisa
vn
elisa
test
gave
conflict
result
sera
hors
follow
administr
one
dose
kill
vaccin
prepar
artervac
fort
dodg
laboratori
pair
sera
one
tabl
seroconvert
vn
test
titr
follow
vaccin
addit
sera
demonstr
vn
antibodi
follow
vaccin
although
high
enough
score
vn
comparison
set
pair
serum
sampl
seroconvert
elisa
follow
vaccin
strongest
absorb
chang
seen
mean
absorb
rise
follow
vaccin
respect
contrari
result
vn
test
serum
elisa
three
antigen
prior
vaccin
eav
isolatespecif
sera
eav
vaccin
antisera
arvac
kill
bucyru
neutralis
bucyru
strain
eav
vn
test
elisa
howev
bucyru
deriv
antisera
recognis
sera
exhibit
conflict
elisa
vn
test
result
compris
vn
vn
field
sera
none
vaccin
hors
vngroup
sera
elisa
recombin
antigen
deriv
differ
viral
protein
remain
sera
elisa
one
viral
protein
antigen
either
n
g
l
vn
sera
group
elisato
recombin
antigen
elisa
previous
demonstr
follow
infect
viru
neutralis
equin
sera
recognis
g
l
fusion
protein
strongli
gs
n
fusion
protein
inconsist
poorli
chirnsid
et
al
present
studi
reactiv
panel
recombin
fusion
protein
compris
complet
small
part
eav
orf
use
defin
region
within
amino
acid
immunoreact
region
viral
nucleocapsid
protein
post
infect
seroposit
equin
sera
recognis
immunoblot
elisa
construct
contain
amino
terminu
n
loss
produc
unreact
protein
immunoblot
elisa
poor
reactiv
elisa
could
due
improp
fold
n
protein
within
construct
vn
sera
recognis
fairli
strongli
immunoblot
complet
failur
react
vn
sera
immunoblot
poorli
elisa
may
due
least
part
linear
epitop
span
beyond
amino
acid
residu
elisa
immunoblot
reactiv
protein
although
exhaust
test
requir
result
indic
immunoreact
epitop
n
contain
within
amino
acid
region
span
residu
import
reactiv
equin
sera
n
gene
eav
highli
conserv
isol
chirnsid
et
al
failur
specif
antisera
isol
react
may
due
differ
immun
respons
individu
anim
rather
antigen
variat
reactiv
elisa
correl
well
presenc
vn
antibodi
hors
sera
recent
evid
balasuriya
et
al
balasuriya
et
al
deregt
et
al
chirnsid
et
al
b
indic
major
neutralis
epitop
eav
locat
g
l
due
locat
protein
characterist
lack
potenti
glycosyl
site
unlik
n
would
target
neutralis
antibodi
failur
n
fusion
protein
induc
vn
respons
rabbit
support
predict
basi
comparison
eav
vn
test
result
antigen
choic
use
serodiagnost
antigen
elisa
antigen
confirm
presenc
eavspecif
antibodi
control
vn
postinfect
vn
eavspecif
equin
sera
test
capabl
identifi
vaccin
induc
seroconvers
absenc
detect
vn
antibodi
respons
addit
elisa
sera
conflict
vn
rg
l
elisa
confirm
rg
l
elisa
result
correctli
one
featur
rg
l
rn
elisa
abil
detect
elisa
vnsampl
postvaccin
amongst
field
sampl
submit
diagnosi
appear
due
increas
sensit
elisa
vn
test
detect
subpopul
antibodi
neutralis
eav
total
pool
equin
antibodi
reactiv
viral
protein
current
time
elisa
appear
suitabl
prescreen
sampl
prior
perform
confirmatori
vn
test
elisa
sampl
could
immedi
acceler
clear
hors
eav
report
hors
eav
antibodi
statu
widespread
use
antigen
elisa
confirm
suitabl
standalon
diagnost
reagent
replac
vn
test
